Physician profile
Michael A Swerdin
NPI 1295730273
$4,933.42
in general payments reported to CMS, 2019-2025
21 companies · $940 in 2025
The $940 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $476 · 2021: $494 · 2022: $729 · 2023: $674 · 2024: $938 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,534 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,534.01 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $797.43 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $602.61 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $566.02 | 2019-2023 | |
| Oyster Point Pharma, INC. | $562.15 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $412.43 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Sun Pharmaceutical Industries INC. | $339.99 | 2019-2025 | Cequa, Xelpros |
| Abbvie INC. | $297.32 | 2023-2025 | Durysta, Lumigan |
| Mallinckrodt Hospital Products INC. | $231.30 | 2021-2025 | Acthar |
| Biotissue Holdings INC. | $199.44 | 2019-2024 | |
| Alcon Vision LLC | $171.69 | 2022-2025 | Simbrinza, Tryptyr |
| Dompe US, INC. | $168.61 | 2019-2024 | Oxervate |
| Harrow Eye, LLC | $108.49 | 2024-2025 | Vevye |
| Aerie Pharmaceuticals, INC. | $107.10 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $92.26 | 2019-2021 | |
| Glaukos Corporation | $80.63 | 2023-2024 | Idose |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $67.35 | 2022-2024 | Dextenza |
| Sight Sciences, INC. | $56.94 | 2022-2024 | Tearcare System, Omni Surgical System |
| Eyevance Pharmaceuticals LLC | $25.80 | 2019-2021 | |
| Shire North American Group INC | $19.35 | 2019 | |
| Mallinckrodt Enterprises LLC | $16.70 | 2019 | |
| Quidel Corporation | $9.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Swerdin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.